

DAFTAR PUSTAKA

1. Adeloeye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. *J Glob Health*. 2015;5(2):1–17.
2. Safiri S, Carson-Chahhoud K, Noori M, Nejadghaderi SA, Sullman MJM, Ahmadian Heris J, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: Results from the Global Burden of Disease Study 2019. *BMJ*. 2022;2:1–13.
3. Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronic obstructive pulmonary disease. *Clin Chest Med*. 2014;35(1):7–16.
4. Balitbangkes. Riset Kesehatan Dasar 2013. Kementerian Kesehatan RI. Jakarta; 2013. h.85-7.
5. Whittaker H, Rubino A, Müllerová H, Morris T, Varghese P, Xu Y, et al. Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. *Int J COPD*. 2022;17(February):427–37.
6. Sadatsafavi M, Sin DD, Zafari Z, Criner G, Connett JE, Lazarus S, et al. The Association between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model. *Am J Epidemiol*. 2016;184(9):681–9.
7. GOLD. Global Initiative for Chronic Obstructive Lung. Global Strategy for The Diagnosis, Management, and Prevention of Chronic Obstructive

- Pulmonary Disease. 2024. p.99-113.
8. Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. *Clin Chest Med.* 2020;41(3):421–38.
 9. Sun YC. Chronic obstructive pulmonary disease in primary healthcare institutions in China: Challenges and solutions. *Chronic Dis Transl Med.* 2020;6(4):219–23.
 10. Taylan M, Demir M, Kaya H, Selimoglu Sen H, Abakay O, Carkanat AI, et al. Alterations of the neutrophil–lymphocyte ratio during the period of stable and acute exacerbation of chronic obstructive pulmonary disease patients. *Clin Respir J.* 2017;11(3):311–7.
 11. Sari AP, Ratnawati R, Aniwidyaningsih W, Andarini SL, Yunus F. Neutrophyl – Lymphocyte Ratio (NLR) and C-Reactive Protein (CRP) Levels in Stable and Exacerbated Chronic Obstructive Pulmonary Disease (COPD) Patients in Persahabatan Hospital Jakarta. *Respir Sci.* 2022;2(2):78–91.
 12. Perhimpunan Dokter Paru Indonesia Pedoman Diagnosis dan Penatalaksanaan di Indonesia. *Penyakit Paru Obstruktif Kronik.* Edisi 3. Jakarta; 2023. h. 93–106.
 13. Li J, Sun S, Tang R, Qiu H, Huang Q, Mason TG, et al. Major air pollutants and risk of COPD exacerbations: A systematic review and meta-analysis. *Int J COPD.* 2016;11(1):3079–91.
 14. Pascual-González Y, López-Sánchez M, Dorca J, Santos S. Defining the role of neutrophil-to-lymphocyte ratio in COPD: A systematic literature

- review. *Int J COPD*. 2018;13:3651–62.
15. Garth J, Barnes JW, Krick S. Targeting cytokines as evolving treatment strategies in chronic inflammatory airway diseases. *Int J Mol Sci*. 2018;19(11):1–19.
 16. Sander Talman, Djamin RS, Grooten- MJJH, Boers, Aerts2 JGJ., Eerden MM van der. Mediators Of Inflammation In COPD. *Pulm Med Respir Res*. 2019;5(26):1–10.
 17. McKee TJ, Perlman G, Morris M, Komarova S V. Extracellular matrix composition of connective tissues: a systematic review and meta-analysis. *Sci Rep*. 2019;9(1):1–15.
 18. Sheng F, Chen L, Lin H, Wu H. Systematic review and meta-analysis: value of venous blood gas in the diagnosis of acute exacerbation of chronic obstructive pulmonary disease in Emergency Department. *Ann Palliat Med*. 2022;11(4):1473–81.
 19. Cukic V. The changes of arterial blood gases in COPD during four-year period. *Med Arh*. 2014;68(1):14–8.
 20. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol*. 2016;138(1):16–27.
 21. Jasper AE, Mciver WJ, Sapey E, Walton GM. Understanding the role of neutrophils in chronic inflammatory airway disease. *F1000Research*. 2019;8(1):557–74.
 22. Rosales C. Neutrophil: A cell with many roles in inflammation or several cell types? *Front Physiol*. 2018;9(2):1–17.
 23. Rosales C, Lowell CA, Schnoor M, Uribe-Querol E. Neutrophils: Their

- role in innate and adaptive immunity 2017. *J Immunol Res.* 2017;2017:2–4.
24. Gashynova K. COPD exacerbation: Influence of severity and type of systemic inflammation on the hospitalizations rate. *Pharma Innov J.* 2015;3(11):22–5.
25. Prakoeswa FR. Peranan Sel Limfosit Dalam Imunologi: Artikel Review. *J Sains dan Kesehat.* 2020;2(4):525–37.
26. Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. *Int J Mol Sci.* 2022;23(7):1–10.
27. Lonergan M, Dicker AJ, Crichton ML, Keir HR, Van Dyke MK, Mullerova H, et al. Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. *Respir Res.* 2020;21(1):1–10.
28. Uzeloto JS, de Toledo-Arruda AC, Silva BS de A, Golim M de A, Braz AMM, Grigoletto FF de LI, et al. Systemic cytokine profiles of CD4+ t lymphocytes correlate with clinical features and functional status in stable COPD. *Int J COPD.* 2020;15:2931–40.
29. Celli BR, Fabbri LM, Aaron SD, Agusti A, Brook R, Criner GJ, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: The rome proposal. *Am J Respir Crit Care Med.* 2021;204(11):1251–8.
30. Uzunlar EA, Yildiran H, Kokturk N, Kilic H, Hasanoglu HC. Obesity, Charlson comorbidity index, and neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: relationship to disease severity. *Bratisl Med J.* 2023;124(7):520–6.

31. Furutate R, Ishii T, Motegi T, Hattori K, Kusunoki Y, Gemma A, et al. The neutrophil to lymphocyte ratio is related to disease severity and exacerbation in patients with chronic obstructive pulmonary disease. *Intern Med.* 2016;55(3):223–9.
32. Verdoia M, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G. Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease: Results from a Large Cohort Study. *Angiology.* 2016;67(1):75–82.
33. Benites-Zapata VA, Hernandez A V., Nagarajan V, Cauthen CA, Starling RC, Wilson Tang WH. Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure. *Am J Cardiol.* 2015;115(1):57–61.
34. Cho JH, Cho HJ, Lee HY, Ki YJ, Jeon ES, Hwang KK, et al. Neutrophil-lymphocyte ratio in patients with acute heart failure predicts in-hospital and long-term mortality. *J Clin Med.* 2020;9(2):1–16.
35. Berkovitch A, Younis A, Grossman Y, Segev S, Kivity S, Sidi Y, et al. Relation of Neutrophil to Lymphocyte Ratio to Risk of Incident Atrial Fibrillation. *Am J Cardiol.* 2019;123(3):396–401.
36. Wu S, Yang YM, Zhu J, Ren JM, Wang J, Zhang H, et al. Impact of Baseline Neutrophil-to-Lymphocyte Ratio on Long-Term Prognosis in Patients With Atrial Fibrillation. *Angiology.* 2021;72(9):819–28.
37. Liu X, Zhang Q, Wu H, Du H, Liu L, Shi H, et al. Blood neutrophil to lymphocyte ratio as a predictor of hypertension. *Am J Hypertens.* 2015;28(11):1339–46.

38. Zhang X, Wei R, Wang X, Zhang W, Li M, Ni T, et al. The neutrophil-to-lymphocyte ratio is associated with all-cause and cardiovascular mortality among individuals with hypertension. *Cardiovasc Diabetol*. 2024;23(1):1–11.
39. Lianos GD, Alexiou GA, Exarchos C, Rausei S, Mitsis M, Voulgaris S. Prognostic significance of neutrophil-to-lymphocyte ratio in several malignancies: Where do we stand? *Biomark Med*. 2020;14(3):169–72.
40. Ozyurek BA, Ozdemirel TS, Ozden SB, Erdogan Y, Kaplan B, Kaplan T. Prognostic value of the neutrophil to lymphocyte ratio (NLR) in lung cancer cases. *Asian Pacific J Cancer Prev*. 2017;18(5):1417–21.
41. Bar-Ad V, Palmer J, Li L, Lai Y, Lu B, Myers RE, et al. Neutrophil to lymphocyte ratio associated with prognosis of lung cancer. *Clin Transl Oncol*. 2017;19(6):711–7.
42. Fan H, Wu F, Liu J, Zeng W, Zheng S, Tian H, et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Ann Transl Med*. 2021;9(5):1–14.
43. Wang Y, Li Z, Li F. Impact of Previous Pulmonary Tuberculosis on Chronic Obstructive Pulmonary Disease: Baseline Results from a Prospective Cohort Study. *Comb Chem High Throughput Screen*. 2022;26(1):93–102.
44. Malefane L, Maarman G. Post-tuberculosis lung disease and inflammatory role players: can we characterise the myriad inflammatory pathways involved to gain a better understanding? *Chem Biol Interact*. 2024;387(8):1–9.

45. Berhane M, Melku M, Amsalu A, Enawgaw B, Getaneh Z, Asrie F. The role of neutrophil to lymphocyte count ratio in the differential diagnosis of pulmonary tuberculosis and bacterial community-acquired pneumonia: A cross-sectional study at Ayder and Mekelle Hospitals, Ethiopia. *Clin Lab*. 2019;65(4):527–33.
46. Niu Y, Xing Y, Li J, Shui W, Gu Y, Zhang C, et al. Effect of Community-Acquired Pneumonia on Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *COPD J Chronic Obstr Pulm Dis*. 2021;18(4):417–24.
47. Çil E, Karadeniz G, Yenigün S, Çoraplı G. Evaluation of the relationships between procalcitonin and neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with pneumonia. *Eur Rev Med Pharmacol Sci*. 2022;26(9):3200–5.
48. Kuikel S, Pathak N, Poudel S, Thapa S, Bhattarai SL, Chaudhary G, et al. Neutrophil–lymphocyte ratio as a predictor of adverse outcome in patients with community-acquired pneumonia: A systematic review. *Heal Sci Reports*. 2022;5(3):1–10.
49. Ekinci O, Ekinci A. The connections among suicidal behavior, lipid profile and low-grade inflammation in patients with major depressive disorder: a specific relationship with the neutrophil-to-lymphocyte ratio. *Nord J Psychiatry*. 2017;71(8):574–80.
50. Özyurt G, Binici NC. The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in adolescent obsessive-compulsive disorder: Does comorbid anxiety disorder affect inflammatory response? *Psychiatry Res*. 2019;272:311–5.

51. Peleg N, Schmilovitz-Weiss H, Shamah S, Schwartz A, Dotan I, Sapoznikov B. Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett's esophagus. *Endoscopy*. 2021;53(8):774–81.
52. Zeren S, Bayhan Z, Kocak FE, Duzgun SA, Kahraman C, Ekici MF, et al. Diagnostic value of platelet / lymphocyte ratio and neutrophil / lymphocyte ratio in investigations for helicobacter pylori gastritis. *Int J Clin Exp Med*. 2016;9(2):5102–6.
53. Atay A, Karahan F, Gunes Ö, Gunay S, Dilek ON. From dyspepsia to complicated peptic ulcer: new markers in diagnosis and prognosis. *Eur Rev Med Pharmacol Sci*. 2023;27(4):1352–9.
54. Jo YS, Kim KJ, Rhee CK, Yoo KH, Jung KS, Park YB. Prevalence, characteristics, and risk of exacerbation in young patients with chronic obstructive pulmonary disease. *Respir Res*. 2022;23(1):1–8.
55. Krishnanand KK, D CRNBM, Praveen JVMD, D PDRM. The Use of Cauda-70 Score in Predicting the Prognosis in Patients with Acute Exacerbations of COPD *Abstract* : 2022;21(10):21–5.
56. Hu Y, Xie J, Chang X, Chen J, Wang W, Zhang L, et al. Characteristics and Predictors of Abstinence Among Smokers of a Smoking Cessation Clinic in Hunan China. *Front Public Heal*. 2021;9(3):1–12.
57. Adelaye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med*. 2022;10(5):447–58.

58. Santus P, Di Marco F, Braido F, Contoli M, Corsico AG, Micheletto C, et al. Exacerbation Burden in COPD and Occurrence of Mortality in a Cohort of Italian Patients: Results of the Gulp Study. *Int J COPD*. 2024;19:607–17.
59. Raleigh VS. Trends in life expectancy in EU and other OECD countries. *OECD Heal Work Pap*. 2019;(108):14–5.
60. Cho SJ, Stout-Delgado HW. Aging and Lung Disease. *Annu Rev Physiol*. 2020;82:433–59.
61. Gea J, Ausín P, Martínez-Llorens JM, Barreiro E. Respiratory muscle senescence in ageing and chronic lung diseases. *Eur Respir Rev*. 2020;29(157):1–8.
62. Nugroho A. Persepsi Anak Muda Terhadap Keberadaan Lansia Di Indonesia. *J Urban Sociol*. 2020;2(2):44–55.
63. Lu FY, Chen R, Li N, Sun XW, Zhou M, Li QY, et al. Neutrophil-to-lymphocyte ratio predicts clinical outcome of severe acute exacerbation of copd in frequent exacerbators. *Int J COPD*. 2021;16:341–9.
64. Ellingsen J, Janson C, Bröms K, Lisspers K, Ställberg B, Högman M, et al. Neutrophil-to-lymphocyte ratio, blood eosinophils and COPD exacerbations: a cohort study. *ERJ Open Res*. 2021;7(4):1–11.
65. Assagaf H, Felty Q. Gender, estrogen, and obliterative lesions in the lung. *Int J Endocrinol*. 2017;17:1–13.
66. Balitbangkes. Riset Kesehatan Dasar 2018. Lembaga Penerbit Balitbangkes. Jakarta; 2018. h 320-338.
67. Han MLK, Arteaga-Solis E, Blenis J, Bourjeily G, Clegg DJ, DeMeo D, et al. Female sex and gender in lung/sleep health and disease: Increased

- understanding of basic biological, pathophysiological, and behavioral mechanisms leading to better health for female patients with lung disease. *Am J Respir Crit Care Med*. 2018;198(7):850–8.
68. Kulhánová I, Forman D, Vignat J, Espina C, Brenner H, Storm HH, et al. Tobacco-related cancers in Europe: The scale of the epidemic in 2018. *Eur J Cancer*. 2020;139:27–36.
69. Hu Y, Long H, Cao Y, Guo Y. Prognostic value of lymphocyte count for in-hospital mortality in patients with severe AECOPD. *BMC Pulm Med*. 2022;22(1):1–7.
70. Guo-Parke H, Linden D, Weldon S, Kidney JC, Taggart CC. Mechanisms of virus-induced airway immunity dysfunction in the pathogenesis of COPD disease, progression, and exacerbation. *Front Immunol*. 2020;11(June):1–10.
71. Kato A, Hanaoka M. Pathogenesis of COPD (Persistence of Airway Inflammation): Why Does Airway Inflammation Persist After Cessation of Smoking? Springer. 2017;1(4):57–72.
72. Terzikhan N, Verhamme KMC, Hofman A, Stricker BH, Brusselle GG, Lahousse L. Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study. *Eur J Epidemiol*. 2016;31(8):785–92.
73. Pando-Sandoval A, Ruano-Ravina A, Candal-Pedreira C, Rodríguez-García C, Represas-Represas C, Golpe R, et al. Risk factors for chronic obstructive pulmonary disease in never-smokers: A systematic review. *Clin Respir J*. 2022;16(4):261–75.
74. Lee SJ, Kim SW, Kong KA, Ryu YJ, Lee JH, Chang JH. Risk factors for

- chronic obstructive pulmonary disease among never-smokers in Korea. *Int J COPD*. 2015;10:497–506.
75. Gai X, Allwood B, Sun Y. Post-tuberculosis lung disease and chronic obstructive pulmonary disease. *Chin Med J (Engl)*. 2023;136(16):1923–8.
76. Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW, et al. Acute exacerbation of COPD. *Respirology*. 2016;21(7):1152–65.
77. Restrepo MI, Sibila O, Anzueto A. Pneumonia in COPD. *Tuberculosis Respir Dis*. 2018;81:187–97.
78. Zeng J, Zhou C, Yi Q, Luo Y, Wei H, Ge H, et al. Validation of the Rome Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbation: A Multicenter Cohort Study. *Int J COPD*. 2024;19:193–204.
79. Ejiofor SI, Stolk J, Fernandez P, Stockley RA. Patterns and characterization of COPD exacerbations using real-time data collection. *Int J COPD*. 2017;12:427–34.
80. Sato M, Chubachi S, Sasaki M, Haraguchi M, Kameyama N, Tsutsumi A, et al. Impact of mild exacerbation on COPD symptoms in a Japanese cohort. *Int J COPD*. 2016;11(1):1269–78.
81. Alparslan Bekir S, Tuncay E, Gungor S, Yalcinsoy M, Sogukpinar Ö, Gundogus B, et al. Can red blood cell distribution width (RDW) level predict the severity of acute exacerbation of chronic obstructive pulmonary disease (AECOPD)? *Int J Clin Pract*. 2021;75(11):1–7.
82. El-Gazzar AG, Kamel MH, Elbahnasy OKM, El-Naggat MES. Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients. *Expert Rev Respir Med*. 2020;14(1):111–6.

83. Alkhayat K, Abdelhameed R, Gadallah D. The effect of neutrophil-lymphocyte ratio in patients with COPD in Sohag University Hospital. *Egypt J Chest Dis Tuberc.* 2021;70(3):331–6.
84. Özsarı E, Koçak MZ. Clinical significance of mean platelet volume/lymphocyte ratio and mean platelet volume/platelet ratio in the exacerbation of chronic obstructive pulmonary disease. *Eur Res J.* 2019;5(6):1001–6.

